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There is a need for a better differentiation of aggressive tumors in prostate cancer to design
a tailored treatment for each patient, preferably by a minimally invasive analysis of blood
samples. In a previous study, we discovered a decrease of plasma levels of carnosine dipep-
tidase 1 (CNDP1) in association with aggressive prostate cancer. Now this relation has been
investigated and characterized further by generating several new antibodies for extended
analysis of CNDP1 in plasma. Multi-antibody sandwich assays were developed and applied
to 1214 samples from two Swedish cohorts that conﬁrmed decreased levels of CNDP1 inSandwich immunoassay
Prostate cancer
Plasma biomarker
Suspension bead array
Carnosine dipeptidase 1
plasma from patients with advanced disease. Therein, data from CNDP1 assays allowed a
better differentiation between tumor N stages than clinical tPSA, but did not when classify-
ing T or M stages. Further investigations can now elucidate mechanisms behind decreasing
levels of CNDP1 in plasma and primary in regards to lymph node metastasis.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.Abbreviations: CAB, commercial antibody; CNDP1, carnosine dipept
Human Protein Atlas; GLM, general linear model; LOESS, local regression
nMFi, normalized median ﬂuorescence intensity; KW, Kruskal–Wallis o
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. Introduction
n contemporary practice, most patients with prostate cancer
PCa) are diagnosed following a PSA test and are asymptomatic
t the time of diagnosis. Although serum PSA has a low speci-
city for prostate cancer, it can be used to single out patients
ith advanced disease. Efforts to improve our understand-
ng of disease onset, diagnosis and progression through the
nalysis of prostate tissue, serum, plasma, urine or seminal
uid offers various entry points for discovery driven analy-
is. One of these is proteomics that aims at the determination
f protein constituents and their isoforms in a give sample
1]. For this type of analysis several technologies are available
o allow high-throughput analysis of prostate cancer sam-
les. This includes afﬁnity-based proteomics with a growing
umber of available binding molecules toward human pro-
eins [2], and combined with microarray assays, multi-parallel
mmunoassays of many samples can be achieved [3].
In a previous study, we used antibodies from the Human
rotein Atlas [4] and suspension bead arrays [5] to protein pro-
le plasma from patients with prostate cancer and respective
ontrols. There we identiﬁed the protein carnosine dipepti-
ase 1 (CNDP1), as a potential marker for aggressive prostate
ancer. CNDP1 is a secreted protein of 57kDa found in human
lood and the central nervous system, with an approximate
erum concentration of 20g/ml in healthy individuals [6,7]
nd acts as homodimer [8] and displays carboxypeptidase
nd dipeptidase activity, degrading carnosine and homo-
arnosine [9]. It is furthermore a glycoprotein that carries
-glycosylation on C-terminal residues 322 and 382 [10] and
NDP1 has been reported to form a complex with protease
nhibitor alpha-2 macroglobulin [11]. Thus far, CNDP1 has
een mainly mentioned with the susceptibiliy to nephropa-
hy in type 2 diabetes through common genetic variants [12]
nd carnosine, substrate of the CNDP1, is believed to act as
protective factor in diabetic nephropathy [13]. A ﬁrst link
etween CNDP1 and prostate cancer was discovered in our
ntibody array based analysis that revealed a decreased level
f CNDP1 in plasma of patients suffering from an aggressive
orm of the disease [5].
The aims of this study were to improve the CNDP1 detec-
ion in plasma samples by developing multiple sandwich
mmunoassays and thereby to investigate the association of
he decrease in CNDP1 levels with these assays in additional
rostate cancer plasma samples. Further, we aimed to ana-
yze whether the reported/predicted glycosylation status [10]
r any interacting partner of CNDP1 are causing a differential
etection in relation prostate cancer severity.
. Materials and methods
.1. Samples
our sets of plasma samples were studied from three inde-
endent collections (see Supplementary Table 2A for details).
hese samples were analyzed in independent experiments
nd this is described in four phases (phases I–IV). This
ncluded two collections 79 heparin plasma samples (Skånecs 2 ( 2 0 1 4 ) 14–24 15
University Hospital, Sweden, denoted phase I) and 90 EDTA
plasma samples (Cancer Prostate in Sweden, phase II) that
had been analyzed previously using a single antibody based
approach [5]. Phase III was built on 317 additional samples
from CAPS. For phase IV, 728 heparin plasma samples were
obtained during a collection period of 2004–2010 at Skåne Uni-
versity Hospital.
2.2. Deglycosylation and Western Blot
Plasma samples were diluted 10× in 50mM NaPO4, 0.1% (v/v)
SDS and 1% Triton X100 and incubated at 96 ◦C for 3min
and 10U PNGaseF (Peptide-N-glycosidase F, Roche Diagnos-
tics) were added for 24h incubation at 37 ◦C. Moreover, 300ng
of recombinant CNDP1 (TP310312, Origene) were diluted and
prepared as above. The extent of deglycosylation of CNDP1
was then evaluated with Western Blot with HPA-1 as detec-
tion antibody. Per lane, 50ng of recombinant CNDP1 and
2g plasma samples depleted from human serum albumin
(HSA) and immunoglobulin G (IgG) by the use of Afﬁbody
molecules (Afﬁbody AB) coupled to Sulfolink matrix (Pierce) as
described elsewhere [10], were loaded to an SDS-PAGE (4–12%
Bis Tris, Invitrogen). Proteinswere transferred ontomembrane
(0.45m PVDF, Invitrogen) according to the manufacturers
protocol and transfer was conﬁrmed with Ponceau (Pierce)
staining. Membranes were blocked in 5% milk powder (Sem-
per) in TBS-T for 1h. Primary antibodies were incubated at
optimized concentrations in blocking buffer at 4 ◦C for 16h.
Membranes were washed in TBS-T for 3× 5min followed by
incubation with HRP-conjugated polyclonal swine anti-rabbit
antibody (Dako) in blocking buffer at RT for 1h. A ﬁnal wash
was followed by detection with TMBM substrate (Moss Inc.).
The antibodies were also directly compared using a multi-
screen apparatus (Mini-PROTEAN II, Bio-Rad).
2.3. Antibodies and epitope mapping
For the described immunoassays, different capture antibodies
were utilized (Table 1 and supplementary Table 1). Monoclonal
antibodies were generated in mice toward antigens 1 and
2 (Fig. 3A) and obtained from Atlas Antibodies AB, Sweden.
The polyclonal detection antibody AF2489 (RnD Systems) was
labeled with biotin (NHS-PEG4Biotin, Pierce) at a 50-fold molar
excess over 2h at 4 ◦C and stored after adding Tris-HCl (pH 8.0)
at a 250-foldmolar excess. All anti-CNDP1antibodieswere epi-
tope mapped on bead arrays using 15-mer peptides with a 10
residue overlap spanning CNDP1 antigens 1 and 2 (Fig. 3A) as
described previously [14]. For Alfa-2 macroglobulin, antibod-
ies and protein standard were used from a kit (DY1913, RnD
Systems).
2.4. Bead based sandwich assays
Antibodies were coupled to magnetic carboxylated beads
(MagPlex, Luminex Corp.) according to the manufactur-
ers protocol and as described previously [5]. The cou-
pling efﬁciency for each antibody was determined via R-
phycoerythrin-labeled anti-rabbit (Jackson ImmunoResearch
Laboratories), Alexa Flour 555-labeled anti-goat (Invitrogen)
and R-phycoerythrin-labeled anti-mouse (Moss Inc.) IgG
16 translat ional proteomics 2 ( 2 0 1 4 ) 14–24
Table 1 – List of antibodies directed toward (A) CNDP1 and (B) other proteins. For numeric epitope/immunogen
speciﬁcation, the amino acid region of the respective full-length protein is listed.
(A) CNDP1 antibodies
Name Antibody ID CNDP1 region Epitopes Species
HPA-1a HPA008933 32–133 32–46; 57–76; 102–116; 122–133 Rabbit
HPA-1.F1a N/A 32–133 32–46 Rabbit
HPA-1.F15a N/A 32–133 102–116 Rabbit
CAB-1a,b AF2489 28–507 62–81; 77–96; 107–121; 387–401; 457–471 Goat
MAB-1.1a 3A6 32–133 47–61 Mouse
MAB-1.2a 5B2 32–133 47–61 Mouse
(B) Other antibodies
Name Antibody ID Target protein Immunogen Homology to CNDP1 (%)
HPA-3a HPA036899 CNDP2 154–249 55
HPA-4a HPA036898 CNDP2 23–96 53
HPA-5a HPA002265 A2M 603–748 7
CAB-4a A0001 HSA Full-length 13
CAB-5a Rabbit IgG sera N/A N/A N/Aa Capture antibody.
b Detection antibody.
antibodies. Bead arrays were then created by combing equal
amounts of beads, where each population of a distinct color-
code and carrying a particular antibody. Plasma samples were
thawed at RT, centrifuged for 10min at 3000 rpm, and trans-
ferred into a microtiter plate (Abgene) according to a designed
layout. The plates were centrifuged (1min at 3000 rpm) and
samples were diluted 1:10 in 1× PBS in 96-well microtiter
plates with a liquid handler (TECAN, Freedom Evo 150). Sam-
ples were diluted 50× in assay buffer composed of 0.5% (w/v)
polyvinyl alcohol and 0.8% (w/v) polyvinylpyrrolidone in 0.1%
casein (all Sigma) in PBS supplemented with 0.5mg/ml rab-
bit IgG (Bethyl Laboratories). The samples were treated in a
thermocycler at 56 ◦C for 30min and 23 ◦C for 15min. Then,
45l was combined with 5l of a bead array in 384-well ﬂat-
bottomed half-area microtiter plates (Greiner), and incubation
took place O/N on a shaker at RT and 650 rpm. Beads were
washed on a magnet 3× with 100l of PBST (1× PBS, pH 7.4,
0.1% Tween20) using a plate washer (EL406, BioTek). This was
followed by 1h with 50l of 0.1g/ml labeled detection anti-
bodyCAB-1 (RnDSystems), 3× washing, 10minwith a solution
containing 0.1% paraformaldehyde in PBS. Beadswerewashed
again, and 50l of 0.5g/ml R-phycoerythrin-labeled strepta-
vidin (Invitrogen) in PBSTwas added and incubated for 20min.
Finally, beads were washed and measured in 60l of PBST
using a dedicated instrument (FlexMap3D, Luminex Corp.).
2.5. Assessment of apparent detection limits
Limits of detection were determined for both sample and anti-
gen dilutions. For the sample dilution series, a pool of plasma
samples was diluted over several concentrations in 1× PBS
and then subjected to the 50× dilution in the assay buffer. For
the detection limit assessment with antigen, a plasma pool
was diluted 1:10 with 1× PBS, spiked with 0–50,000ng/ml of
recombinant CNDP1 (Origene) and diluted 50× in assay buffer,
yielding a spike-in sample serieswith 0–1000ng/ml CNDP1. All
samples were heat treated before 45l were combined with5l of the bead array, as described above. The apparent limit
of detection was calculated using a ﬁve-parametric logistic
regression as the concentration of spiked antigen correspond-
ing to MFI values 3× standard deviation above background.
A spike-in without replicates was included in the ﬁnal assay
of the phase IV sample collection, and detection limits were
determined as 30% above the background intensity. For anal-
ysis with A2M (DY1938, RnD Systems), a spike-in series with
0–100ng/ml antigen was prepared.
3. Data analysis
For each bead identity, 32 counted events were required as
absolute minimum to qualify the median ﬂuorescence inten-
sity (MFI) for further analysis (personal communication with
Luminex Corp.). All data processing and analysis was con-
ducted using the R environment [15]. During phases III and
IV the MFI values were corrected for order in the sequential
readout; within each 96-well-assay plate using Pareto scaling
(phase III) denoted scaled intensity and within each 384-well-
assay plate using LOESS (phase IV) denoted nMFI, and used
in further statistical analysis. The variability within a mea-
surement was evaluated with the coefﬁcient of variation (CV)
as the ratio of standard deviation and mean and protein pro-
ﬁles both within and between measurements were correlated
using Pearson’s correlation test. The CV calculation was per-
formed with nMFI adjusted so that the minimum intensity
value per antibody equaled zero.
The association of the cancer associated confounder age
and also total PSA plasma concentration was tested with
a generalized linear model (GLM). The association between
CNDP1 level and tumor stage was tested with a GLM includ-
ing age as a covariate with data from sample sets in phases
II–IV. For phase IV samples, the tumor stageswere converted to
integers from 1 to 3 for T0/T1, T2 and T3/T4, respectively. Fur-
thermore Kruskal–Wallis one-way analysis of variance (KW)
was used to assess the association between phase I’s PCa risk
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roups or phase IV’s N or M stage sample groups and CNDP1
etection level. A GLM was applied to test for T stage asso-
iated protein proﬁles and Kruskal–Wallis rank sum test to
etermine N and M stage associated protein proﬁles. Multiple
esting was accounted for using the Benjamini and Hochberg
ethod.
The receiver operating characteristic (ROC) area under the
urve (AUC) and 95% conﬁdence interval (CI) with 2000 boot-
trap replicates were calculated per antibody (phases I–III)
nd for all antibodies combined (phase IV) including available
linical covariates age, total PSA and the number of positive
iopsies; in the classiﬁcation between controls and advanced
ases (phase I; low and high PCa risk, phase II and 3; indolent
nd aggressive PCa and phase IV; T0/T1 and T3/T4, N0 vs N1
nd M0 vs M1 sample groups). The multivariate models were
tted using a generalized linear model (R-package GLM) prior
OC analysis (R-package pROC).
.1. Mass spectrometric analysis of immunocapture
DTA plasma was provided by Atlas Antibodies AB, Sweden
nd originated from threemales and three females all without
nown disease diagnosis. This mixture of plasma was diluted
:300 in assay buffer and heat treated as above. Antibodies
PA-1, MAB-1.1 and normal rabbit IgG (CAB-5) and normal
ouse IgG (sc-2025, Santa Cruz Biotechnology) were coupled
o Luminex beads as above, and beads carrying the different
ntibodies were incubated separately with 1ml of heat treated
lasma samples overnight at RT on gentle rotation. After incu-
ation beads were washed 3× in PBS/0.03% CHAPS (Sigma)
nd 2× in 0.03% CHAPS, to be then re-suspended in 50l
mmonium bicarbonate 50mM to perform on beads trypsin
igestion. Captured proteins were reduced with dithiothreitol
DTT) 1mMand alkylated by iodoacetamide (IAA) 4mM. Alkyl-
tion was quenched adding 1mM DTT. Proteins were digested
y trypsin (Promega) overnight at 37 ◦C and peptides were sep-
rated from beads, dried and re-suspended in buffer A (97%
ater, 3% acetonitrile (ACN), 0.1% formic acid (FA)).
In each LC–MS run, the LC auto sampler (HPLC 1200 sys-
em, Agilent Technologies) injected 5l of sample into a C18
uard desalting column (Zorbax 300SB-C18, 5mm× 0.3mm,
mbead size, Agilent).We thenuseda 15 cm longC18picofrit
olumn (100m internal diameter, 5m bead size, Nikkyo
echnos Co., Tokyo, Japan) installed on to the nano electro-
pray ionization (NSI) source. Solvent A was 97% water, 3%
cetonitrile (ACN), 0.1% formic acid (FA); and solvent B was
% water, 95% ACN, 0.1% FA. At a constant ﬂow of 0.4l/min,
he linear gradient went from 2% B up to 40% B in 45min, fol-
owed by a steep increase to 100% B in 5min. Online LC–MS
as performed using a hybrid LTQ-Orbitrap Velos mass spec-
rometer (Thermo Scientiﬁc). Precursors were isolated with
2m/z window. We enabled “preview mode” for FTMS mas-
er scans, which proceeded at resolution of 30,000 (proﬁle
ode). Data-dependent MS/MS (centroid mode) followed in
wo stages: ﬁrstly, the top 5 ions from the master scan were
elected for collision induced dissociation (CID, at 35% energy)
ith detection in the ion trap (ITMS); and after, the same 5 ions
nderwent higher energy collision dissociation (HCD, at 37.5%
nergy) with detection in the orbitrap (FTMS).cs 2 ( 2 0 1 4 ) 14–24 17
All MS/MS spectra were searched by Sequest under
the software platform Proteome Discoverer (PD, v1.3.0.339,
Thermo Scientiﬁc) using a target-decoy strategy. The refer-
ence database used was the human reference proteome set
from uniprot.org (2013-04-18). Precursor mass tolerance of
10ppm and product mass tolerances of 0.02Da for HCD-FTMS
and 0.36Da for CID-ITMS were used. Additional settings were:
trypsinwith 1missed cleavage; carbamidomethylation on cys-
teine as ﬁxed modiﬁcation; and oxidation of methionine as
variable modiﬁcation. Precursor peak areas were quantiﬁed
using the “precursor ions area detector” module of Proteome
Discoverer. Peptides found at 1% FDR (false discovery rate)
were used by the protein grouping algorithm in PD to infer
protein identities.
4. Results
In the presented study, we investigated CNDP1 glycosyla-
tion in plasma by using Western blot analysis and developed
sandwich immunoassays by raising monoclonal anti-CNDP1
antibodies. These binders were then epitope mapped for iden-
tifying matching pairs of antibodies to develop sandwich
assays. During four rounds of analysis, here called phases I–IV,
these assays were utilized to determine difference in CNDP1
plasma levels through in sample sets from two independent
cohorts, as outlined in Fig. 1.
4.1. Analysis of CNDP1 glycosylation
In previous work [5], Western blot analysis of plasma revealed
bands at ±55kDa and ±150kDa when using HPA008933
(denoted HPA-1). To investigate whether glycosylation of
plasma CNDP1 plays a role in the differential proﬁles of
aggressive and less aggressive forms, plasma as well as
recombinant CNDP1 protein were exposed to PNGaseF treat-
ment to facilitate enzymatic removal of predicted N-linked
glycan structures. As shown in Fig. 2A for recombinant
CNDP1, two proximate bands were observed at ±55kDa and
upon incubation with PNGaseF the upper band disappeared,
which suggested that one CNDP1 isoform was glycosylated
when expressed in HEK293T cells alongside an isoform that
appeared not to carry a glycosylation. In plasma, PNGaseF
treatment of controls and cases (group at risk) was effective
for both to a similar extend and a shift toward lower molec-
ular masses was observed for bands at ±55kDa as well as
the band at ±150kDa (Fig. 2B and C). Importantly, the bands
at now ±50kDa revealed concordant decrease in intensity as
found in previous observations and analysis of plasma with-
out PNGaseF. This suggests that glycosylation status of CNDP1
detected in Western blot analysis did not differ between case
and control groups.
4.2. Generation and characterization of CNDP1
antibodiesA main aim of this study was to develop sandwich immunoas-
says for CNDP1 to determine the protein in plasma other then
using discovery tools such as antibody arrays and to allow for
a better selectivity of the analysis. For this matter, monoclonal
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Fig. 1 – Study overview. (A) The investigation of CNDP1 in relation to prostate cancer was organized into phases I–IV using
particular plasma sample collections for each. (B) The illustration refers to the transition of single binder discovery to
analysis with bead based sandwich immunoassays that used several different capture antibodies targeting CNDP1 in
parallel.
antibodies toward residues 32–133 of CNDP1 were raised. Prior
to further analysis, all antibodies listed (Supplementary Table
1) were epitope mapped using peptide bead arrays of 15-mer
peptides covering two CNDP1 fragments covering N-terminal
residues, respectively (Fig. 3A). As previously described [14],
this information was then further used to purify fractions
form the polyclonal antibody HPA-1 based on peptides. Out
of a total of 23 antibodies, including HPAs, MABs and CABs,
CNDP1 epitope maps of 6 were shown in Fig. 3.
In addition, Western blot analysis was performed using
plasma, and as shown in Supplementary Figure 1, congruent,
single bands between 50 and 75kDa were observed for the two
monoclonal antibodies (MAB-1.1 and MAB-1.2) as well as HPA-
1 and HPA-1.F15. As a note, antibodies raised against CNDP2
did not reveal any bands in the MW range of CNDP1. A second
band observed at ±150kDa was common for HPA-1, HPA-1.F15
as well as for CAB-1. Upon comparing this to the detec-
tion using an antibody toward alpha-2-macroglublin (A2M;
HPA002265 listed as HPA-5), a plasma protein known to inter-
act with proteases [11], a band at 150kDa was most prominent
besides other at higher and lower molecular masses (Supple-
mentary Figure 1). This observation either suggests that the
complex CNDP1 andA2M interacting via A2M’s bait regionwas
detected in plasma when assuming that two different anti-
bodies (HPA-1, HPA-1.F15 and CAB-1) used for Western blot
analysis reveal a speciﬁc detection of CNDP1. Otherwise, it
suggested that the two antibodies also recognize an isoformof A2M of about 150kDa in Western blot analysis. To fur-
ther study this observation, sandwich assays for CNDP1 (see
below) andA2Mwere used in parallel by applying each of these
respective detection antibodies separately onto one bead array
built with CNDP1 and A2M antibodies. As shown in Supple-
mentary Figure 2 using spiked recombinant CNDP1 or A2M,
no substantial degree of off-target recognition was observed
and therefore suggested that A2M was not recognized by the
employed CNDP1 sandwich assays.
We further utilized mass spectrometry to identify pro-
teins being captured by antibodies immobilized on beads. As
summarized in Fig. 3B for HPA-1 and MAB-1.1 several CNDP1
peptides were identiﬁed as being captured and being discrete
from analysis performed using either normal rabbit IgG (CAB-
5) or normal mouse IgG. This again supported that previous
single antibody capture analysis [5] revealed proﬁles of CNDP1
and also did not revealed any presence of A2M.
4.3. Development of sandwich immunoassays
To select antibodies for the detection of CNDP1 via a sand-
wich immunoassay, all antibodies were coupled to distinct
bead populations for a parallel capture reaction. Each capture
antibody targeted mapped regions of CNDP1 (Supplementary
Table 1) and different detection antibodies were evaluated
for to build matching pairs. Using plasma samples to assess
the performance, 3× HPA, 1× CAB and 2× MAB antibodies
translat ional proteomics 2 ( 2 0 1 4 ) 14–24 19
Fig. 2 – Western blot analysis of CNDP1 N-glycosylation. (A) Recombinant CNDP1, (B) a plasma pool and (C) 4 individual
plasma samples from the phase I sample collection with high and low PCa risk, exposed to PNGaseF (+). (A) The apparent
molecular mass of the recombinant protein CNDP1 decreased with exposure to PNGaseF (indicated with arrows) and no
upper band was detected. (B, C) Both the upper and lower bands (indicated with arrows) shifted in apparent molecular mass
with exposure to PNGaseF. (C) Relative WB intensity of protein bands between 51 and 64kDa (lower band) comparing
samples from individuals with low and high risk for prostate cancer were concordant with results from the sandwich
immunoassay (data not shown here). PNGaseF referred to Peptide-N-glycosidase F and (+) indicated that samples were
exposed to this enzyme.
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
0 100 200 300 400 500
CNDP1 [a.a.]
CNDP2
antigen 3
antigen 4
CAB-1
MAB-1.2
MAB-1.1
antigen 1
antigen 2
CNDP1
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
IIIIIIIIIIIIIII IIIIIIIIIIIIIIIIIIII IIIIIIIIIIIIIII IIIIIIIIIIII
IIIIIIIIIIIIIII
IIIIIIIIIIIIIII
IIIIIIIIIIIIIII
IIIIIIIIIIIIIII
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII IIIIIIIIIIIIIII IIIIIIIIIIIIIII IIIIIIIIIIIIIII
IIIIII IIIIIIIII IIIIIIIIIII IIIIIIIIIIIIII
IIIIIIIIIIIIII IIIIIIIIIIII IIIIIIIIIIIII IIIIIIIIIIIIII
II IIIIII IIIIIII IIIIIIIII IIIIIIIIIII IIIIIIIIIIIIIIIIIIIIIII III IIIIIIIIIIIIIIIIIIIIII IIIIIIIIIIIIIII IIIIIIIIIIII IIIIIIIIIIIII IIIIIIIIIIIIIIIIIIIIIII I IIII IIIII I IIIIIIIIIIIIIIIIIII IIIIIIIIIIIIIIIII IIIII I II IIIII IIIIIIIIIIIIIIII III IIIIIIIIIIIIIIIIIIIIIIIII III
HPA-1.15
HPA-1.1
HPA-1
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
0 100 200 300 400 500
CNDP1 [a.a.]
MAB-1.1
antigen 1
CNDP1
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
HPA-1
B
A
Fig. 3 – CNDP1 epitopes and peptides. (A) Protein sequences of CNDP1 (gray bar, top) and CNDP2 (blue bar, bottom) were
aligned to display antigens, epitope regions for the antibodies HPA-1, 1.1 and 1.15, MAB-1.1 and 1.2 and CAB-1 (black bar).
(B) Mass spectrometric analysis of immunoprecipitated proteins captured from plasma using beads coupled with HPA-1 or
MAB-1.1 revealed several CNDP1 peptides. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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Fig. 4 – Sandwich assay for CNDP1. (A) Plasma was diluted in a series of concentrations and analyzed with sandwich pair of
HPA-1 and CAB-1 and a sample dilution factor of 1/500 (gray dashed line) was used for the subsequent sandwich
immunoassays. (B) The apparent limit of detection was determined at 2ng/ml using recombinant protein CNDP1 spiked
into diluted plasma. Vertical dashed line: detection limit; horizontal dashed line: 3× standard deviation above background;
Dotted line: background.
chosen as capture reagent revealed the highest intensity fold
change, when comparing samples with low and high PCa risk.
In addition, apparent limit of detection (<30ng/ml) and tech-
nical variance (CV<10%) were used as selection criteria for
employing 6 different antibodies in further analysis, as shown
in Table 1 and in combination with a polyclonal detection
antibody (CAB-1). A sample dilution series was analyzed with
two sandwich immunoassays (Fig. 4 and Supplementary ﬁg-
ure 3) and intensities from CNDP1 targeting pairs decreased
with sample dilution, following a sigmoidal dilution curve. For
the following analysis of patient samples (phase IV), we sup-
plemented the 6 capture antibodies with 4 other antibodies
and one empty bead (Table 1) to conﬁrm the detected levels of
CNDP1 in association to PCa severity via different epitopes.
4.4. Analysis of CNDP1 in two prostate cancer patient
cohortsAtﬁrst, previous results generatedwith the single binder assay
from the analysis of the discovery cohort (phase I, n=79)
and ﬁrst veriﬁcation (phase II, n=90) sample sets [5] were
Fig. 5 – CNDP1 sandwich assays. The boxplots display CNDP1 in
(A) phase I, (B) phase II, and (C) phase III using capture antibodyreproduced with the sandwich assays using the pair HPA-1
with CAB-1 (Fig. 5A and B). For phases I/II, the data showed
a separation of p=0.0004 (KW, CNDP1∼PCa risk) and p=0.006
(GLM, CNDP1∼PCa stage) and ROCAUCs 0.84 and 0.67 (Table 2;
Supplementary Figure 4). There was no statistically signiﬁcant
association between age-adjusted CNDP1 intensity and PCa
stage (GLM p>0.05, age-adjusted-CNDP1∼PCa stage). Next,
the analysis was extended into phase III sample collection
(n=368; Fig. 5C). There, no statistically signiﬁcant association
of CNDP1 with aggressive prostate cancer was found (GLM
p>0.05) nor did CNDP1 outperform total PSA or age in ROC
analysis, as shown in Table 2.
We continued with analyzing a new sample collection,
denoted phase IV, that was built on 728 samples. In this anal-
ysis, the detected levels of CNDP1 highly correlated between
the 6 antibodies (rho 0.84–0.97), and a decrease in CNDP1 was
found for primary tumor stage T3 and T4, distant metastasis
M1 and in samples annotated with PCa spreading to regional
lymph nodes N1 (Fig. 6). When combining the data from all
CNDP1 antibodies into one classiﬁer, an improved separation
in the comparisons of M1 vs M0, N1 vs N0 or T3/T4 vs T0/T1
tensity ranges per sample group for the sample collections
HPA-1 and CAB-1 for detection.
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Table 2 – Classiﬁcation of PCa risk or aggressive PCa with ROC analysis. The variables CNDP1 intensity, total plasma PSA
and age (age available for phases II and III) were included in the classiﬁcation analysis, multivariate models ﬁtted using a
GLM and the performance of each classiﬁcation evaluated via AUC values with 95% conﬁdence intervals.
Phase Antibody Comparison (samples) Variables AUC CI
I
a tPSA 1.00 1.0–1.0
HPA-1 High (n=17) vs CNDP1+ tPSA 1.00 1.0–1.0
HPA-1 Low risk (n=23) CNDP1 0.84 0.7–1.0
II
HPA-1 tPSA/age+ tPSA/CNDP1+age+ tPSA 1.00 1.0–1.0
HPA-1 Indolent (n=30) CNDP1+age 0.91 0.8–1.0
a vs Age 0.81 0.7–0.9
HPA-1 Aggressive (n=29) CNDP1 0.67 0.5–0.8
III
HPA-1b Age+ tPSA/age+CNDP1+ tPSA 0.90 0.9–1.0
HPA-1b Indolent (n=147) Age+CNDP1/Age 0.85 0.8–0.9
a tPSA 0.73 0.6–0.8
HPA-1.F15 vs CNDP1 0.56 0.5–0.7
HPA-1.F1 CNDP1 0.55 0.4–0.7
HPA-1 Aggressive (n=44) CNDP1 0.55 0.5–0.6
a Clinical data only.
b As well as HPA-1.F1 or HPA-1.F15.
Fig. 6 – CNDP1 levels in tumors. The level of CNDP1 detected in samples from phase IV using a sandwich assay. Lower
detection levels (nMFI) of CNDP1 were observed with all 6 antibody pairs in sample subsets corresponding to the most
advanced stages of PCa; (A) T3/T4, (B) N1 and (C) M1, here displayed with data from a sandwich assay with a monoclonal
capture (MAB-1.1) and polyclonal detection (CAB-1) antibody anti-CNDP1. The numbers of samples within each sample
group were listed in the ﬁgure.
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bas achieved (Table 3A–C, Supplementary Table 2B). CNDP1
ntensity proﬁles classiﬁed tumor stages T0/T1 from T3/T4
ith AUC 0.77 when combing all pairs and age, but again
otal PSA levels outperformed even a classiﬁcation includ-
ng CNDP1, age, gender and the number of positive biopsies
Table 3A). CNDP1 showed to improve the classiﬁcation for
otal PSA in the comparison of M1 vs M0 stages when com-
ined with age (AUC=0.95, Table 3B). Most interestingly, when
sing CNDP1 and age in the classiﬁcation of N1 vs N0 samples,
lasma CNDP1 levels resulted in an improved classiﬁcation
ompared to total PSA, age or the number of positive biop-
ies (AUC ranged 0.66–0.87, Table 3C). In essence, CNDP1 did
ot outperform total PSA when comparing prostate cancer
atient M or T stages, but it showed to improve the detec-
ion of regional lymph node metastasis when differentiating
etween N1 and N0.5. Discussion
In the presented study, plasma from more than 1000 individ-
uals was analyzed in the context of prostate cancer using a
sandwich immunoassay developed for the protein CNDP1. Our
study included epitope mapping of antibodies, the develop-
ment of a multiplexed, single-target sandwich immunoassay
and investigations to resolve protein glycosylation. We con-
ﬁrmed decreasing CNDP1 levels in plasma of patients at a later
stage of prostate cancer, in particular of those classiﬁed with
metastasis of the lymph nodes.Today, PSA is the only biomarker used in daily practice
for diagnosis and in follow-up of prostate cancer patients.
Although recent improvements in imaging by multimodality
MRI and PET/CT scan, we lack a sensitive method to detect
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Table 3 – Classiﬁcation of tumor stage with ROC analysis. The variables CNDP1 intensity, total plasma PSA, age and the
number of positive biopsies were included in the classiﬁcation analysis of (A) primary tumor stage (T0/T1 vs T3/T4), (B)
distant metastasis (M0 vs M1) and (C) presence of metastasis in regional lymph nodes (N0 vs N1). Multivariate models
were ﬁtted using a GLM and the performance of each classiﬁcation was evaluated via AUC values with 95% conﬁdence
intervals (CI).
(A) T stages
Capture antibody Variable AUC CI
b tPSA 0.88 0.8–0.9
Antibody panela CNDP1+age+biopsy+ tPSA 0.87 0.8–0.9
Antibody panela CNDP1+age+ tPSA 0.86 0.8–0.9
b Age+ tPSA 0.85 0.8–0.9
Antibody panela CNDP1+age+biopsy 0.78 0.7–0.8
Antibody panela CNDP1+age 0.77 0.7–0.8
MAB-1.1; MAB-1.2 or HPA-1.F15 CNDP1+age 0.76 0.7–0.8
CAB 1; HPA-1 or HPA-1.F1 CNDP1+age 0.75 0.7–0.8
b Age 0.74 0.7–0.8
b Biopsy 0.67 0.6–0.7
(B) M stages
Antibody Variable AUC CI
Antibody panela CNDP1+age+ tPSA 0.95 0.9–1.0
Antibody panela CNDP1+age+biopsy+ tPSA 0.94 0.9–1.0
b Age+ tPSA 0.93 0.9–1.0
b tPSA 0.92 0.8–1.0
Antibody panela CNDP1+age+biopsy 0.75 0.6–0.9
Antibody panela CNDP1+age 0.73 0.6–0.9
HPA-1.F1 CNDP1+age 0.71 0.6–0.8
MAB-1.1 CNDP1+age 0.70 0.6–0.8
MAB-1.2 CNDP1+age 0.68 0.6–0.8
HPA-1 or HPA-1.F15 CNDP1+age 0.67 0.5–0.8
CAB-1 CNDP1+age 0.64 0.5–0.8
b Biopsy 0.62 0.5–0.7
b Age 0.54 0.4–0.7
(C) N stages
Capture antibody Variable AUC CI
Antibody panela CNDP1+age+biopsy+ tPSA 0.94 0.9–1.0
Antibody panela CNDP1+age+biopsy 0.91 0.8–1.0
Antibody panela CNDP1+age+ tPSA 0.90 0.8–1.0
Antibody panela CNDP1+age 0.87 0.7–1.0
HPA-1.F1 CNDP1+age 0.76 0.5–1.0
MAB-1.2 CNDP1+age 0.75 0.5–1.0
MAB-1.1 CNDP1+age 0.74 0.5–1.0
HPA-1 or HPA-1.F15 CNDP1+age 0.70 0.4–1.0
CAB 1 CNDP1+age 0.66 0.4–1.0
b Age+ tPSA 0.62 0.4–0.9
b Biopsy 0.62 0.4–0.9
b Age 0.61 0.4–0.9
b tPSA 0.58 0.3–0.9
AB-1.a Antibody panel: HPA-1; HPA-1.1; HPA-1.15; MAB-1.1; MAB-1.2 and C
b Clinical data only.
lymph node metastases in prostate cancer patients. Surgi-
cal lymph node dissection is still golden standard thus new
markers to predict increase risk of lymph node metastases
are highly warranted. Our study therefore suggests investi-
gating CNDP1 further using functional analysis to elucidate,
which mechanisms contribute to its decreasing plasma levels
and how such changes can be addressed by therapy. Hereby,
a focus could be on lymphatic systems and its contribution
to decreases of CNDP1, but it will also be required to assess
whether this is a prostate or gender speciﬁc ﬁnding. Therewere a few number of N1 cases in the analyzed cohorts, so
further replication in independent sample collections and
cohorts is anticipated to conﬁrm the observed relation of
CNDP1 to advanced PCa.
We had previously speculated on the inﬂuence of gly-
cosylation status on CNDP1 detection [5]. It is known that
carbohydrate components of glycoproteins perform critical
biological functions in protein sorting, immune and recep-
tor recognition, inﬂammation, pathogenicity, metastasis, and
other cellular processes [16]. N-glycans may play a role in
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ancer progression, as malignant cells have been shown to
ynthesize longer chains of N-glycans [17,18] and alterations
f speciﬁc glycans have been observed in metastatic prostate
ancer [19]. Using antibody-based detection in combination
ith plasma and recombinant protein being subjected to
nzymatic deglycosylation, we could not ﬁnd that indications
f CNDP1 level decrease were primarily effected by their state
f glycosylation. Further analysis would be required to better
nderstand CNDP1 glycosylation in prostate cancer, but our
urrent data did not support previous speculations, as differ-
ntial detectionofCNDP1appearedunrelated to glycosylation.
Also, the relation of detected protein levels where corrob-
rated for off-target detection. First for CNDP2, a peptidase
ound as a cytosolic homodimer with 2 acetylation sites and
as recently been found in proteomic analysis of Parkinson’s
isease [20]. CNDP2 has a 55% sequence similarity to CNDP1
ut as shown by the panel of applied capture antibodies, our
ata did not reveal that CNDP2 would be detected instead of
NDP1. The highly abundant protease inhibitor A2M, which
an form a stable complex with CNDP1, was hypothesized to
onstitute the approximately 150kDa protein band observed
ith WB using HPA-1, HPA-1.F15 and CAB-1, as A2M or A2M-
NDP1. The interaction between A2M and anti-CNDP1 HPA-1,
AB-1, MAB-1.1 and MAB-1.2 were studied using sandwich
ssays. There, no cross-reactivity toward A2M protein was
bserved thus suggesting that the secondband inWestern blot
nalysis was either not A2M or particular to the Western blot
nalysis. Given that Western blot display proteins enriched
t their respective molecular mass location, the higher local
ensity of A2M regions similar to CNDP1 may have lead this
ntibody to recognize A2M. We also demonstrate the possibil-
ty to combine mass spectrometric read-out with bead based
ssays, as proteins being captured by the immobilized anti-
odies can be identiﬁed as being CNDP1 speciﬁc by on bead
rypsin digestion. Even though this was achieved on a single
ample only, it supports this and previous studies in providing
vidence for CNDP1 detection in plasma. In the mass spec-
rometric analysis, no peptides were assigned to A2M and
trengthen the above observation of an A2M-free isoform of
NDP1.
To our current knowledge, this is one of the ﬁrst studies
hat follows up on discoveries made with antibody arrays and
t also represents a path on how to develop sandwich assays
rom such single binder assays. This may therefore be an
mportant and noteworthy contribution to existing proteomic
tudies in plasma, as it addresses the challenge of off-target
inding through the use of several antibodies with distinct
pitopes on one target protein. Further so, we anticipate that
roteins detectable in plasma with single binder assays, such
s PSA [5], should also be detectable using sandwich assays.
evertheless, sandwich assays are still not a ﬁst line tool to
iscover new candidates for disease classiﬁcation, thus argue
or new sandwich assay technologies to be developed for a ﬁrst
ine discovery. Until then, single binder assays may remain a
rst choice in afﬁnity proteomics during screening, but prefer-
bly not during veriﬁcation. Multiplexing offers the inclusion
f several target assays into a single analysis. Rather than sup-
lementing other target assays, we chose to determine one
rotein via parallel capture reactions through the detection
ith one detection antibody. It might be argued for that usingcs 2 ( 2 0 1 4 ) 14–24 23
a single detection antibody could still not rule out that off-
target interactions are being measured. But as shown here by
the use of six capture antibodies that were generated in differ-
ent species, targeting different epitopes, while being utilized
in a multiplex fashion, correlating intensity proﬁles (median
rho 0.93) were obtained to support the detection of CNDP1.
In conclusion, our study shows the development and appli-
cation of a multiplexed sandwich assay for a single target
via the use of distinct epitopes of CNDP1. This conﬁrmed
decreasing levels of CNDP1 in plasma from patients suffer-
ing from prostate cancer and revealed that CNDP1 levels were
particularly different in patients with diagnosed lymph node
metastasis. This reﬁned understanding of CNDP1 association
may contribute to alternative detection of prostate cancer and
lymph node status.
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